One business day earlier than expected, rare disease specialist Amicus Therapeutics Inc. secured a long-sought FDA approval for its oral Fabry disease therapy, Galafold (migalastat), on Friday, the company's first U.S.-approved medicine. The initial U.S. list price will be $315,000 per year.